Charles River Laboratories International (CRL) 10-Q 4 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 26, 2016	Apr. 18, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	CHARLES RIVER LABORATORIES INTERNATIONAL INC
Entity Central Index Key	1,100,682
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 26, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		47,177,976

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Income Statement [Abstract]
Service revenue	$ 220,701	$ 196,780
Product revenue	134,167	123,634
Total revenue	354,868	320,414
Costs and expenses:
Cost of services provided (excluding amortization of intangible assets)	147,349	136,306
Cost of products sold (excluding amortization of intangible assets)	66,751	64,448
Selling, general and administrative	82,944	71,397
Amortization of intangible assets	6,352	5,258
Operating income	51,472	43,005
Other income (expense):
Interest income	263	284
Interest expense	(4,211)	(3,024)
Other income (expense), net	4,026	(8,313)
Income from continuing operations, before income taxes	51,550	31,952
Provision for income taxes	13,975	331
Income from continuing operations, net of income taxes	37,575	31,621
Loss from discontinued operations, net of income taxes	(26)	(7)
Net income	37,549	31,614
Less: Net income attributable to noncontrolling interests	(406)	(73)
Net income attributable to common shareholders	$ 37,143	$ 31,541
Basic:
Continuing operations attributable to common shareholders (in dollars per share)	$ 0.80	$ 0.67
Discontinued operations (in dollars per share)	0	0
Net income attributable to common shareholders (in dollars per share)	0.80	0.67
Diluted:
Continuing operations attributable to common shareholders (in dollars per share)	0.78	0.66
Discontinued operations (in dollars per share)	0	0
Net income attributable to common shareholders (in dollars per share)	$ 0.78	$ 0.66

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 37,549	$ 31,614
Foreign currency translation adjustment and other	(7,796)	(32,669)
Cumulative translation adjustment related to intercompany loan forgiveness	0	(2,341)
Amortization of net loss and prior service benefit included in net periodic cost for pension and other post-retirement benefit plans	390	729
Other comprehensive income (loss), before income taxes	30,143	(2,667)
Income tax expense related to items of other comprehensive income	142	217
Comprehensive income (loss), net of income taxes	30,001	(2,884)
Less: Comprehensive income related to noncontrolling interests	(127)	(73)
Comprehensive income (loss) attributable to common shareholders	$ 29,874	$ (2,957)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 26, 2016	Dec. 26, 2015
Current assets:
Cash and cash equivalents	$ 157,375	$ 117,947
Trade receivables, net	287,178	270,068
Inventories	97,101	93,735
Prepaid assets	33,573	30,198
Other current assets	62,164	47,286
Total current assets	637,391	559,234
Property, plant and equipment, net	664,437	677,959
Goodwill	434,056	438,829
Intangible assets, net	265,384
Deferred tax assets	26,355	40,028
Other assets	76,095	71,643
Total assets	2,103,718	2,068,497
Current liabilities:
Current portion of long-term debt and capital leases	21,382	17,033
Accounts payable	43,897	36,675
Accrued compensation	57,072	72,832
Deferred revenue	80,297	81,343
Accrued liabilities	89,433	89,494
Other current liabilities	16,056	12,544
Current liabilities of discontinued operations	1,852	1,840
Total current liabilities	309,989	311,761
Long-term debt, net and capital leases	840,481	845,997
Deferred tax liabilities	45,297	48,223
Other long-term liabilities	87,364	89,062
Long-term liabilities of discontinued operations	7,415	7,890
Total liabilities	$ 1,290,546	$ 1,302,933
Commitments and contingencies
Redeemable noncontrolling interest	$ 28,744	$ 28,008
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.01 par value; 120,000 shares authorized; 86,051 shares issued and 47,114 shares outstanding as of March 26, 2016 and 85,464 shares issued and 46,698 shares outstanding at December 26, 2015	861	855
Additional paid-in capital	2,426,984	2,397,960
Retained earnings	47,681	10,538
Treasury stock, at cost 38,937 shares and 38,766 shares as of March 26, 2016 and December 26, 2015, respectively	(1,552,885)	(1,540,738)
Accumulated other comprehensive loss	(142,817)	(135,548)
Total equity attributable to common shareholders	779,824	733,067
Noncontrolling interests	4,604	4,489
Total equity	784,428	737,556
Total liabilities, redeemable noncontrolling interest and equity	2,103,718	2,068,497
Client relationships, net
Current assets:
Intangible assets, net	202,888	213,374
Other intangible assets, net
Current assets:
Intangible assets, net	$ 62,496	$ 67,430

CONDENSED CONSOLIDATED BALANCE5

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Mar. 26, 2016	Dec. 26, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	86,051,000	85,464,000
Common stock, shares outstanding (in shares)	47,114,000	46,698,000
Treasury stock (in shares)	38,937,000	38,766,000

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Cash flows relating to operating activities
Net income	$ 37,549	$ 31,614
Less: Loss from discontinued operations, net of income taxes	(26)	(7)
Income from continuing operations, net of income taxes	37,575	31,621
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Depreciation and amortization	24,655	22,368
Amortization of debt issuance costs and discounts	409	423
Stock-based compensation	9,941	9,674
Deferred income taxes	12,522	9,474
Gain on venture capital investments	(3,082)	(1,271)
Gain on bargain purchase	16	0
Other, net	1,405	(917)
Changes in assets and liabilities:
Trade receivables, net	(16,279)	(18,302)
Inventories	(3,081)	431
Other assets	(3,432)	(5,448)
Accounts payable	9,352	3,038
Accrued compensation	(16,025)	(17,252)
Deferred revenue	(979)	1,321
Accrued liabilities	(444)	(2,742)
Taxes payable and prepaid taxes	(13,649)	(20,639)
Other liabilities	(365)	(527)
Net cash provided by operating activities	38,539	11,252
Cash flows relating to investing activities
Acquisition of businesses and assets, net of cash acquired	(318)	(893)
Capital expenditures	(8,250)	(10,648)
Purchases of investments	(6,395)	(9,724)
Proceeds from sale of investments and distributions from venture capital investments	5,700	8,288
Other, net	2,821	684
Net cash used in investing activities	(6,442)	(12,293)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility	49,423	39,828
Proceeds from exercises of stock options	12,514	34,136
Payments on long-term debt, capital lease obligations and revolving credit facility	(49,409)	(23,678)
Purchase of treasury stock	(12,147)	(58,632)
Other, net	6,700	10,280
Net cash provided by financing activities	7,081	1,934
Discontinued operations
Net cash used in operating activities from discontinued operations	(489)	(316)
Effect of exchange rate changes on cash and cash equivalents	739	(8,681)
Net change in cash and cash equivalents	39,428	(8,104)
Cash and cash equivalents, beginning of period	117,947	160,023
Cash and cash equivalents, end of period	$ 157,375	$ 151,919

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 26, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission. The year-end condensed consolidated balance sheet data was derived from the Company’s audited financial statements, but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year 2015 . The condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations. The Company’s fiscal year is typically based on a 52 -week year, with each quarter composed of 13 weeks. A 53-week year will occur during the fiscal year 2016, with an additional week included in the fourth quarter. The Company reports its financial performance in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). Use of Estimates The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, redeemable noncontrolling interest, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. Consolidation The Company’s condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies,” in the Company’s Annual Report on Form 10-K for the fiscal year 2015 . Newly Issued Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-09, “Improvements to Employee Share-Based Payment Accounting.” The standard reduces complexity in several aspects of the accounting for employee share-based compensation, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases.” The standard established the principles that lessees and lessors will apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. The ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the full impact this standard will have on its consolidated financial statements and related disclosures but expects to recognize substantially all of its leases on the balance sheet, by recording a right-to-use asset and a corresponding lease liability. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory,” that simplifies the subsequent measurement of inventories by replacing the current lower of cost or market test with a lower of cost or net realizable value test. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” The standard, including subsequently issued amendments, will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. The standard will require an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will be effective for annual and interim periods beginning after December 15, 2017. The Company has not yet selected a transition method and is evaluating the impact the adoption will have on its consolidated financial statements and related disclosures.

Business Acquisitions

Business Acquisitions	3 Months Ended
	Mar. 26, 2016
Business Combinations [Abstract]
BUSINESS ACQUISITIONS	BUSINESS ACQUISITIONS WIL Research On April 4, 2016, the Company acquired WRH, Inc. (WIL Research), a provider of safety assessment and contract development and manufacturing (CDMO) services to biopharmaceutical and agricultural and industrial chemical companies worldwide. The acquisition enhanced the Company’s position as a leading global early-stage contract research organization (CRO) by strengthening its ability to partner with global clients across the drug discovery and development continuum. The preliminary purchase price for WIL Research was approximately $ 585.0 million in cash, which is subject to certain customary adjustments. See Note 7, “Long-Term Debt and Capital Leases.” WIL Research’s safety assessment and CDMO businesses will be reported in the Company’s DSA and Manufacturing reportable segments, respectively. Due to the limited time between the acquisition date and the filing of this Quarterly Report on Form 10-Q, it is not practicable for the Company to disclose the preliminary allocation of purchase price to assets acquired and liabilities assumed. The Company incurred transaction and integration costs in connection with the acquisition of $4.0 million during the three months ended March 26, 2016 , which were included in selling, general and administrative expenses. Oncotest On November 18, 2015 , the Company acquired Oncotest GmbH (Oncotest), a German CRO providing discovery services for oncology, one of the largest therapeutic areas for biopharmaceutical research and development spending. With this acquisition, the Company expanded its oncology services capabilities, enabling it to provide clients with access to a more comprehensive portfolio of technologies, including patient-derived xenograft (PDX) and syngeneic models. The purchase price for Oncotest was approximately $ 36.0 million , including $ 0.3 million in contingent consideration. The acquisition was funded by borrowings on the Company's revolving credit facility. The business is reported in the Company’s DSA reportable segment. The contingent consideration is a one-time payment that could become payable based on the achievement of a revenue target for the fiscal year 2016. If achieved, the payment will become due in the first quarter of the fiscal year 2017. The aggregate, undiscounted amount of contingent consideration that the Company may pay is €2.0 million ( $2.2 million as of March 26, 2016 ). The Company estimated the fair value of this contingent consideration based on a probability-weighted set of outcomes. The purchase price allocation of $ 35.4 million , net of $ 0.6 million of cash acquired, was as follows: November 18, 2015 (in thousands) Trade receivables (contractual amount of $3,546) $ 3,520 Inventories 129 Other current assets (excluding cash) 706 Property, plant and equipment 2,528 Definite-lived intangible assets 13,330 Goodwill 22,894 Other long-term assets 250 Current liabilities (3,456 ) Long-term liabilities (4,470 ) Total purchase price allocation $ 35,431 The purchase price allocations were prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 7,146 19 Developed technology 5,960 19 Other intangible assets 224 3 Total definite-lived intangible assets $ 13,330 The goodwill resulting from the transaction is primarily attributed to the potential growth in the Company's DSA businesses from customers and technology introduced through Oncotest, the assembled workforce of the acquired business and expected cost synergies. The goodwill attributable to Oncotest is not deductible for tax purposes. The Company incurred insignificant transaction and integration costs in connection with the acquisition for the three months ended March 26, 2016 and March 28, 2015 , which were included in selling, general and administrative expenses. Celsis On July 24, 2015 , the Company acquired Celsis Group Limited (Celsis), a leading provider of rapid testing systems for non-sterile bacterial contamination for the biopharmaceutical and consumer products industries. The purpose of this acquisition was to enhance the Company’s portfolio of rapid microbial detection products and services with the addition of a rapid bioburden testing product. The purchase price for Celsis was $214.5 million , including assumed debt and certain liabilities of $ 10.3 million . The acquisition was funded by cash on hand and borrowings on the Company’s revolving credit facility. The business is reported in the Company’s Manufacturing reportable segment. The purchase price allocation of $212.2 million , net of $2.3 million of cash acquired, was as follows: July 24, 2015 (in thousands) Trade receivables (contractual amount of $5,410) $ 5,288 Inventories 10,103 Other current assets (excluding cash) 13,269 Property, plant and equipment 4,639 Definite-lived intangible assets 118,140 Goodwill 105,262 Other long-term assets 537 Short-term debt (9,766 ) Other current liabilities (7,136 ) Long-term liabilities (28,100 ) Total purchase price allocation $ 212,236 The purchase price allocations were prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. From the date of the acquisition through March 26, 2016 , the Company recorded measurement-period adjustments related to the Celsis acquisition that resulted in an immaterial change to the purchase price allocation. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 71,000 16 Developed technology 39,140 14 Trademark and trade names 5,200 14 Non-compete 2,800 5 Total definite-lived intangible assets $ 118,140 The goodwill resulting from the transaction is primarily attributed to the potential growth of the Company’s Manufacturing business from clients introduced through Celsis, the assembled workforce of the acquired business and expected cost synergies. The goodwill attributable to Celsis is not deductible for tax purposes. The Company incurred insignificant transaction and integration costs in connection with the acquisition of for the three months ended March 26, 2016 and March 28, 2015 , which were included in selling, general and administrative expenses. Sunrise On May 5, 2015 , the Company acquired Sunrise Farms, Inc. (Sunrise), a producer of specific-pathogen-free fertile chicken eggs and chickens used in the manufacture of live viruses. The purpose of this business acquisition was to expand the capabilities of the Company’s existing Avian Vaccine Services business. The purchase price of the acquisition was $9.6 million and was funded by cash on hand and borrowings on the Company's revolving credit facility. The business is reported in the Company's Manufacturing reportable segment. The Company recorded a bargain purchase gain of $9.8 million , which represents the excess of the estimated fair value of the net assets acquired over the preliminary purchase price. The bargain purchase gain was recorded in other income (expense), net, in the Company’s consolidated statement of income and was not recognized for tax purposes. The Company believes there were several factors that contributed to this transaction resulting in a bargain purchase gain, including the highly specialized nature of Sunrise’s business falling outside of the seller’s core activities and a limited pool of potential buyers. Before recognizing the gain from the bargain purchase, the Company reassessed its initial identification and valuation of assets acquired and liabilities assumed to validate that all assets and liabilities that the Company was able to identify at the acquisition date were properly recognized. The purchase price allocation of $9.6 million , net of less than $0.1 million of cash acquired, was as follows: May 5, 2015 (in thousands) Trade receivables (contractual amount of $995) $ 965 Inventories 1,518 Other current assets (excluding cash) 973 Property, plant and equipment 13,698 Definite-lived intangible assets 3,400 Current liabilities (925 ) Long-term liabilities (250 ) Fair value of net assets acquired 19,379 Bargain purchase gain (9,821 ) Total purchase price allocation $ 9,558 The identifiable definite-lived intangible assets acquired represent the client relationships intangible, which is being amortized over the estimated useful life of approximately 15 years . The Company incurred insignificant transaction and integration costs in connection with the acquisition for the three months ended March 26, 2016 and March 28, 2015 , which were included in selling, general and administrative expenses.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	3 Months Ended
	Mar. 26, 2016
Supplemental Balance Sheet Information [Abstract]
SUPPLEMENTAL BALANCE SHEET INFORMATION	SUPPLEMENTAL BALANCE SHEET INFORMATION The composition of trade receivables, net is as follows: March 26, 2016 December 26, 2015 (in thousands) Client receivables $ 237,430 $ 230,010 Unbilled revenue 52,134 45,996 Total 289,564 276,006 Less: Allowance for doubtful accounts (2,386 ) (5,938 ) Trade receivables, net $ 287,178 $ 270,068 The composition of inventories is as follows: March 26, 2016 December 26, 2015 (in thousands) Raw materials and supplies $ 17,197 $ 15,998 Work in process 14,295 12,101 Finished products 65,609 65,636 Inventories $ 97,101 $ 93,735 The composition of other current assets is as follows: March 26, 2016 December 26, 2015 (in thousands) Investments $ 18,846 $ 20,516 Prepaid income tax 43,011 26,350 Restricted cash 159 271 Other 148 149 Other current assets $ 62,164 $ 47,286 The composition of other assets is as follows: March 26, 2016 December 26, 2015 (in thousands) Life insurance policies $ 27,130 $ 27,554 Venture capital investments 37,935 32,730 Restricted cash 1,787 1,745 Other 9,243 9,614 Other assets $ 76,095 $ 71,643 The composition of other current liabilities is as follows: March 26, 2016 December 26, 2015 (in thousands) Accrued income taxes $ 15,674 $ 12,168 Accrued interest and other 382 376 Other current liabilities $ 16,056 $ 12,544 The composition of other long-term liabilities is as follows: March 26, 2016 December 26, 2015 (in thousands) Long-term pension liability $ 32,494 $ 34,604 Accrued executive supplemental life insurance retirement plan and deferred compensation plan 30,587 30,188 Other 24,283 24,270 Other long-term liabilities $ 87,364 $ 89,062

Venture Capital Investments and

Venture Capital Investments and Marketable Securities	3 Months Ended
	Mar. 26, 2016
Marketable Securities and Equity-Method Affiliates [Abstract]
VENTURE CAPITAL INVESTMENTS AND MARKETABLE SECURITIES	VENTURE CAPITAL INVESTMENTS AND MARKETABLE SECURITIES Venture Capital Investments The Company invests in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. The Company’s ownership interest in these funds ranges from 3.6% to 12.0% . The Company accounts for these investments, which are variable interest entities, under the equity method of accounting. The Company is not the primary beneficiary because it has no power to direct the activities that most significantly affect the funds’ economic performance. The Company’s total commitments to the entities as of March 26, 2016 was $65.0 million , of which the Company funded $31.0 million through March 26, 2016 . During the three months ended March 26, 2016 and March 28, 2015 , the Company received no dividends from the entities. Subsequent to March 26, 2016, the Company invested in new venture capital funds, which increased the Company’s total commitments by $10.6 million . Marketable Securities The following is a summary of the Company's marketable securities, all of which are classified as available-for-sale: March 26, 2016 Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Mutual fund $ 4,650 $ — $ (98 ) $ 4,552 Total $ 4,650 $ — $ (98 ) $ 4,552 December 26, 2015 Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Mutual fund $ 4,650 $ — $ (141 ) $ 4,509 Total $ 4,650 $ — $ (141 ) $ 4,509 There were no sales of available-for-sale securities during the three months ended March 26, 2016 or March 28, 2015 .

Fair Value

Fair Value	3 Months Ended
	Mar. 26, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE The Company has certain assets, liabilities and redeemable noncontrolling interest recorded at fair value, which have been classified as Level 1, 2, or 3 within the fair value hierarchy: • Level 1 - Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. • Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves and foreign currency spot rates. • Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. The fair value hierarchy level is determined by asset, liability and redeemable noncontrolling interest class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the three months ended March 26, 2016 and March 28, 2015 , there were no transfers between levels. Valuation methodologies used for assets, liabilities and the redeemable noncontrolling interest measured or disclosed at fair value are as follows: • Cash equivalents - Valued at quoted market prices determined through third-party pricing services. • Mutual funds - Valued at the unadjusted quoted net asset value of shares held by the Company. • Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates. • Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments. • Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes. • Redeemable noncontrolling interest - Valued using the income approach based on estimated future cash flows of the underlying business discounted by a weighted average cost of capital. Assets, liabilities and redeemable noncontrolling interest measured at fair value on a recurring basis are summarized below: March 26, 2016 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents $ — $ 221 $ — $ 221 Other current assets: Mutual funds 4,552 — — 4,552 Other assets: Life insurance policies — 19,889 — 19,889 Total assets measured at fair value $ 4,552 $ 20,110 $ — $ 24,662 Other current liabilities: Contingent consideration $ — $ — $ 1,114 $ 1,114 Foreign currency forward contracts — 25 — 25 Other long-term liabilities: Contingent consideration — — 200 200 Redeemable noncontrolling interest — — 28,744 28,744 Total liabilities and redeemable noncontrolling interest measured at fair value $ — $ 25 $ 30,058 $ 30,083 December 26, 2015 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents $ — $ 190 $ — $ 190 Other current assets: Mutual funds 4,509 — — 4,509 Foreign currency forward contracts — 15 — 15 Other assets: Life insurance policies — 20,364 — 20,364 Total assets measured at fair value $ 4,509 $ 20,569 $ — $ 25,078 Other current liabilities: Contingent consideration $ — $ — $ 1,172 $ 1,172 Other long-term liabilities: Contingent consideration — — 198 198 Redeemable noncontrolling interest — — 28,008 28,008 Total liabilities and redeemable noncontrolling interest measured at fair value $ — $ — $ 29,378 $ 29,378 Redeemable Noncontrolling Interest The Company’s redeemable noncontrolling interest resulted from the acquisition of a 75% ownership interest in Vital River. Concurrent with the acquisition, the Company entered into an agreement with the noncontrolling interest holders that provides the Company with the right to purchase the remaining 25% of the entity for cash at its then appraised value beginning in January 2016. Additionally, the noncontrolling interest holders were granted the right to require the Company to purchase the remaining 25% of the entity at its then appraised value beginning in January 2016 for cash. These rights are accelerated if certain conditions are met. As the noncontrolling interest holders can require the Company to purchase the remaining 25% interest, the noncontrolling interest is classified in the mezzanine section of the condensed consolidated balance sheet, which is above the equity section and below liabilities. The following table provides a rollforward of the fair value of the Company’s redeemable noncontrolling interest related to the acquisition of Vital River. Three Months Ended March 26, 2016 March 28, 2015 (in thousands) Beginning balance $ 28,008 $ 28,419 Additions — — Total gains or losses (realized/unrealized): Net income attributable to noncontrolling interest 198 (130 ) Foreign currency translation (186 ) 78 Change in fair value, included in additional paid-in capital 724 1,086 Ending balance $ 28,744 $ 29,453 As of March 26, 2016 , the significant unobservable inputs used in the fair value measurement of the Company’s redeemable noncontrolling interest are the estimated future cash flows based on projected financial data and a discount rate of 18.0% . Significant changes in the timing or amounts of the estimated future cash flows would result in a significantly higher or lower fair value measurement. Significant increases or decreases in the discount rate would result in a significantly lower or higher fair value measurement, respectively. A 1% increase in the discount rate used would result in a $1.7 million decrease in the fair value of the redeemable noncontrolling interest. Contingent Consideration The following table provides a rollforward of the contingent consideration related to the business acquisitions. Three Months Ended March 26, 2016 March 28, 2015 (in thousands) Beginning balance $ 1,370 $ 2,828 Additions 600 675 Payments (674 ) — Total gains or losses (realized/unrealized): Reversal of previously recorded contingent liability and change in fair value 18 (717 ) Ending balance $ 1,314 $ 2,786 The significant unobservable inputs used in the fair value measurement of the Company’s contingent consideration are the probabilities of successful achievement of certain financial targets and a discount rate. Significant increases or decreases in any of the probabilities of success would result in a significantly higher or lower fair value measurement, respectively. Significant increases or decreases in the discount rate would result in a significantly lower or higher fair value measurement, respectively. Debt Instruments The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	3 Months Ended
	Mar. 26, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill The following table provides a rollforward of the Company’s goodwill: Adjustments to Goodwill December 26, 2015 Acquisitions Foreign Exchange March 26, 2016 (in thousands) RMS $ 58,167 $ — $ (14 ) $ 58,153 DSA 247,050 — (1,816 ) 245,234 Manufacturing 133,612 (118 ) (2,825 ) 130,669 Total $ 438,829 $ (118 ) $ (4,655 ) $ 434,056 Intangibles Assets, Net The following table displays intangible assets, net by major class: March 26, 2016 December 26, 2015 Gross Accumulated Amortization Net Gross Accumulated Amortization Net (in thousands) Backlog $ 51,537 $ (51,526 ) $ 11 $ 50,568 $ (50,554 ) $ 14 Technology 56,725 (6,462 ) 50,263 60,350 (5,911 ) 54,439 Trademarks and trade names 11,187 (6,076 ) 5,111 11,495 (5,944 ) 5,551 Other 14,722 (7,611 ) 7,111 14,711 (7,285 ) 7,426 Other intangible assets 134,171 (71,675 ) 62,496 137,124 (69,694 ) 67,430 Client relationships 391,729 (188,841 ) 202,888 396,537 (183,163 ) 213,374 Intangible assets $ 525,900 $ (260,516 ) $ 265,384 $ 533,661 $ (252,857 ) $ 280,804 During the three months ended March 26, 2016 , the Company determined that the carrying values of certain DSA intangible assets were not recoverable and recorded an impairment charge of $ 1.9 million , which was included in costs of services provided (excluding amortization of intangible assets).

Long-Term Debt and Capital Leas

Long-Term Debt and Capital Lease Obligations	3 Months Ended
	Mar. 26, 2016
Debt Disclosure [Abstract]
LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS	LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS Long-Term Debt Long-term debt, net consists of the following: March 26, 2016 December 26, 2015 (in thousands) Term loans $ 385,000 $ 390,000 Revolving credit facility 452,735 446,041 Other long-term debt 196 193 Total debt 837,931 836,234 Less: current portion of long-term debt (20,196 ) (15,193 ) Long-term debt 817,735 821,041 Debt discount and debt issuance costs (7,091 ) (6,805 ) Long-term debt, net $ 810,644 $ 814,236 In April 2015, the Company amended and restated the $ 970M Credit Facility, creating a $ 1.3 billion facility ($ 1.3B Credit Facility) that provides for a $ 400.0 million term loan facility and a $ 900.0 million multi-currency revolving facility. The interest rates applicable to term loans and revolving loans under the Company’s $ 1.3B Credit Facility are, at the Company’s option, equal to either the alternate base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.5% or (3) the one-month adjusted LIBOR rate plus 1% ), or the adjusted LIBOR rate plus an interest rate margin based upon the Company’s leverage ratio. As of March 26, 2016 and December 26, 2015 , the weighted average interest rate on the Company’s debt was 1.49% and 1.33% , respectively. The $1.3B Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to the Company’s business, and negative and affirmative covenants. As of March 26, 2016 , the Company was compliant with all covenants. On March 30, 2016, the Company amended and restated its $ 1.3B credit facility creating a $ 1.65 billion credit facility ($ 1.65B Credit Facility) which (1) extends the maturity date for the credit facility and (2) makes certain other amendments in connection with the Company’s acquisition of WIL Research. The $ 1.65B Credit Facility provides for up to approximately $ 1.65 billion in financing, including an approximately $ 650.0 million term loan facility and a $ 1.0 billion multi-currency revolving facility. The term loan facility matures in 19 quarterly installments with the last installment due March 30, 2021. The revolving facility matures on March 30, 2021, and requires no scheduled payment before that date. The obligations of the Company under the $ 1.65B Credit Facility are secured by substantially all of the assets of the Company. Under specified circumstances, the Company has the ability to increase the term loans and/or revolving line of credit by up to $ 500.0 million in the aggregate. The interest rates applicable to term loans and revolving loans under the $ 1.65B Credit Facility are, at the Company’s option, equal to either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50% , or (3) the one-month adjusted LIBOR rate plus 1% ) or the adjusted LIBOR rate plus an interest rate margin based upon the Company’s leverage ratio. Letters of Credit As of March 26, 2016 and December 26, 2015 , the Company had $5.1 million and $4.9 million in outstanding letters of credit, respectively. Capital Lease Obligations The Company’s capital lease obligations amounted to $31.1 million and $33.6 million as of March 26, 2016 and December 26, 2015 , respectively.

Equity

Equity	3 Months Ended
	Mar. 26, 2016
Equity [Abstract]
EQUITY	EQUITY Earnings Per Share The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Three Months Ended March 26, 2016 March 28, 2015 (in thousands) Numerator: Income from continuing operations, net of income taxes $ 37,575 $ 31,621 Loss from discontinued operations, net of income taxes (26 ) (7 ) Less: Net income attributable to noncontrolling interests (406 ) (73 ) Net income attributable to common shareholders $ 37,143 $ 31,541 Denominator: Weighted-average shares outstanding - Basic 46,642 46,772 Effect of dilutive securities: Stock options, restricted stock units, performance share units and restricted stock 975 1,096 Weighted-average shares outstanding - Diluted 47,617 47,868 Options to purchase approximately 1.0 million and 0.6 million shares for the three months ended March 26, 2016 and March 28, 2015 , respectively, and an insignificant number of restricted stock, restricted stock units (RSUs) and performance share units (PSUs) were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Basic weighted average shares outstanding for the three months ended March 26, 2016 and March 28, 2015 excluded the impact of approximately 1.1 million and 1.2 million shares, respectively, of non-vested restricted stock, RSUs and PSUs. Treasury Shares During the three months ended March 26, 2016 , the Company did not repurchase any shares under its authorized stock repurchase program. The Company repurchased approximately 0.7 million shares for $50.0 million in the three months ended March 28, 2015 . As of March 26, 2016 , the Company had $69.7 million remaining on the authorized stock repurchase program. The Company’s stock-based compensation plans permit the netting of common stock upon vesting of restricted stock, RSUs and PSUs in order to satisfy individual minimum statutory tax withholding requirements. During the three months ended March 26, 2016 and March 28, 2015 , the Company acquired approximately 0.2 million shares for $12.1 million and approximately 0.1 million shares for $8.6 million , respectively. Accumulated Other Comprehensive Income (Loss) Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows: Foreign Currency Translation Adjustment and Other Pension and Other Post-Retirement Benefit Plans Total (in thousands) December 26, 2015 $ (82,977 ) $ (52,571 ) $ (135,548 ) Other comprehensive loss before reclassifications (7,517 ) — (7,517 ) Amounts reclassified from accumulated other comprehensive income (loss) — 390 390 Net current period other comprehensive income (loss) (7,517 ) 390 (7,127 ) Income tax expense — 142 142 March 26, 2016 $ (90,494 ) $ (52,323 ) $ (142,817 ) Foreign currency translation and other includes an insignificant amount of unrealized gains (losses) on available-for-sale marketable securities. Nonredeemable Noncontrolling Interests The Company has investments in several entities, whose financial results are consolidated in the Company’s financial statements, as it has a controlling financial interest in these entities. The interests of the respective noncontrolling parties in these entities have been recorded as noncontrolling interests. The activity within the nonredeemable noncontrolling interests was insignificant during the three months ended March 26, 2016 and March 28, 2015 .

Income Taxes

Income Taxes	3 Months Ended
	Mar. 26, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s overall effective tax rate for the three months ended March 26, 2016 and March 28, 2015 was 27.1% and 1.0% , respectively. For the three months ended March 26, 2016 , the increase was primarily attributable to a benefit recorded during the three months ended March 28, 2015 for a reduction in unrecognized tax benefits and related interest of $ 10.4 million due to the expiration of the statute of limitations associated with pre-acquisition tax positions on forgiveness of debt, as well as the accrual of withholding taxes recorded during the three months ended March 26, 2016 in order to access cash from the Company’s Canadian and Chinese operations for use outside of the U.S. as a result of the reinstatement of the controlled foreign corporation look-through rules during the three months ended December 26, 2015 . During the three months ended March 26, 2016 , the Company’s unrecognized tax benefits increased by $0.1 million to $23.4 million , primarily due to an additional quarter of Canadian Scientific Research and Experimental Development credit reserves offset by favorable foreign exchange movement. The amount of unrecognized income tax benefits that would impact the effective tax rate remained constant at $20.1 million . The amount of accrued interest on unrecognized tax benefits was $1.1 million at March 26, 2016 . The Company estimates that it is reasonably possible that the unrecognized tax benefits will decrease by up to $3.1 million over the next twelve-month period, primarily as a result of the outcome of a pending tax ruling and competent authority ruling. The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits in jurisdictions including the U.S., U.K., China, Japan, France, Germany and Canada. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2012. The Company and certain of its subsidiaries have ongoing tax controversies with various tax authorities in the U.S., Canada, China and France. The Company does not believe that resolution of these controversies will have a material impact on its financial position or results of operations. In accordance with the Company’s policy, the remaining undistributed earnings of its non-U.S. subsidiaries remain indefinitely reinvested as of the end of the three months ended March 26, 2016 as they are required to fund needs outside the U.S. and cannot be repatriated in a manner that is substantially tax free. Income tax expense related to change in unrecognized pension gains, losses and prior service costs was $0.1 million and $0.2 million for the three months ended March 26, 2016 and March 28, 2015 , respectively.

Pension and Other Post-Retireme

Pension and Other Post-Retirement Benefit Plans	3 Months Ended
	Mar. 26, 2016
Compensation and Retirement Disclosure [Abstract]
PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS	PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS The following table provides the components of net periodic cost (benefit) for the Company’s pension plans for the three months ended March 26, 2016 and March 28, 2015 : Pension Plans March 26, 2016 March 28, 2015 (in thousands) Service cost $ 554 $ 1,149 Interest cost 3,364 3,335 Expected return on plan assets (3,992 ) (4,382 ) Amortization of prior service credit (144 ) (151 ) Amortization of net loss 546 880 Net periodic cost $ 328 $ 831 The net periodic cost for the Company’s other post-retirement benefit plan for the three months ended March 26, 2016 and March 28, 2015 was insignificant.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 26, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION The Company has stock-based compensation plans under which employees and non-employee directors may be granted stock-based awards such as stock options, restricted stock, RSUs and PSUs. The following table provides stock-based compensation by the financial statement line item in which it is reflected: Three Months Ended March 26, 2016 March 28, 2015 (in thousands) Cost of revenue $ 1,682 $ 1,501 Selling, general and administrative 8,259 8,173 Stock-based compensation, before income taxes 9,941 9,674 Provision for income taxes (3,514 ) (3,385 ) Stock-based compensation, net of income taxes $ 6,427 $ 6,289 During the three months ended March 26, 2016 , the Company issued approximately 0.6 million stock options with a per share weighted average grant date fair value of $15.04 , approximately 0.2 million RSUs with a per share weighted average grant date fair value of $73.71 and approximately 0.2 million PSUs with a per share weighted average grant date fair value of $79.81 . The maximum number of common shares to be issued upon vesting of PSUs granted during the three months ended March 26, 2016 is approximately 0.4 million .

Foreign Currency Contracts

Foreign Currency Contracts	3 Months Ended
	Mar. 26, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
FOREIGN CURRENCY CONTRACTS	FOREIGN CURRENCY CONTRACTS The Company enters into foreign exchange forward contracts to limit its foreign currency exposure related to intercompany loans that are not of a long-term investment nature. These contracts are recorded at fair value in the Company’s condensed consolidated balance sheet and are not designated as hedging instruments. Any gains or losses on such contracts are immediately recognized in other income (expense), net, and are largely offset by the remeasurement of the underlying intercompany loan balances. The notional amount and fair value of the Company’s foreign currency forward contracts is summarized as follows: Notional Amount Fair Value Balance Sheet Location (in thousands) March 26, 2016 $ 90,412 $ (25 ) Other Current Liabilities December 26, 2015 $ 88,483 $ 15 Other Current Assets The following table summarizes the effect of foreign exchange forward contracts related to intercompany loans denominated in Euros on the Company’s consolidated statement of income: Three Months Ended March 26, 2016 Location of Gain (Loss) Gain (Loss) Recognized (in thousands) Other income (expense), net $ 2,243 The forward contracts outstanding as of March 26, 2016 had durations of 1 month. The Company had no such contracts during the three months ended March 28, 2015 .

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 26, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation Various lawsuits, claims and proceedings of a nature considered normal to its business are pending against the Company. While the outcome of any of these proceedings cannot be accurately predicted, the Company does not believe the ultimate resolution of any of these existing matters would have a material adverse effect on the Company’s business or financial condition. In July 2015, IDEXX Laboratories, Inc. and IDEXX Distribution, Inc. (collectively, IDEXX) filed a complaint in the United States District Court for the District of Delaware alleging the Company has infringed three recently issued patents related to a blood spot sample collection method used in determining the presence or absence of an infectious disease in a population of rodents. On September 21, 2015, the Company timely filed a motion to dismiss the complaint on the grounds that all of the claims are directed to unpatentable subject matter and therefore are invalid. On October, 7, 2015, IDEXX filed an amended complaint which substantially asserts the same patents and infringement allegations as asserted in the original complaint, and on October 26, 2015, the Company timely filed a motion to dismiss this amended complaint. While no prediction may be made as to the outcome of litigation, the Company intends to defend against this proceeding vigorously and therefore an estimate of the possible loss or range of loss cannot be made . In May 2013, the Company commenced an investigation into inaccurate billing with respect to certain government contracts. The Company promptly reported these matters to the relevant government contracting officers, the Department of Health and Human Services’ Office of the Inspector General, and the Department of Justice, and the Company is cooperating with these agencies to ensure the proper repayment and resolution of this matter. The Company has identified approximately $1.5 million of excess amounts billed on these contracts since January 1, 2007, and has recorded a liability for such amount as of March 26, 2016 , as this represents the Company’s best estimate . Because of the ongoing discussions with the government and the complex nature of this matter, the Company believes it is reasonably possible that additional losses may be incurred but cannot at this time make a reasonable estimate of the potential range of loss beyond such estimated liability. Lease Commitments During the three months ended March 26, 2016 , the Company assumed or entered into new lease agreements or exercised options to extend the lease terms for certain existing leases. As a result, the Company’s lease obligations through August 2024 increased by $3.3 million .

Segment Information

Segment Information	3 Months Ended
	Mar. 26, 2016
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION The following table presents revenue and other financial information by reportable segment: Three Months Ended March 26, 2016 March 28, 2015 (in thousands) RMS Revenue $ 124,010 $ 120,011 Operating income 36,533 28,845 Depreciation and amortization 5,281 6,045 Capital expenditures 1,053 2,733 DSA Revenue $ 157,983 $ 140,012 Operating income 30,830 23,516 Depreciation and amortization 11,957 11,139 Capital expenditures 4,707 5,378 Manufacturing Revenue $ 72,875 $ 60,391 Operating income 19,468 16,798 Depreciation and amortization 5,945 3,286 Capital expenditures 2,129 1,566 For the three months ended March 26, 2016 and March 28, 2015 , reconciliations of segment operating income, depreciation and amortization and capital expenditures to the respective consolidated amounts are as follows: Operating Income Depreciation and Amortization Capital Expenditures March 26, 2016 March 28, 2015 March 26, 2016 March 28, 2015 March 26, 2016 March 28, 2015 (in thousands) Total reportable segments $ 86,831 $ 69,159 $ 23,183 $ 20,470 $ 7,889 $ 9,677 Unallocated corporate (35,359 ) (26,154 ) 1,472 1,898 361 971 Total consolidated $ 51,472 $ 43,005 $ 24,655 $ 22,368 $ 8,250 $ 10,648 Revenue for each significant product or service offering is as follows: Three Months Ended March 26, 2016 March 28, 2015 (in thousands) RMS $ 124,010 $ 120,011 DSA 157,983 140,012 Manufacturing 72,875 60,391 Total revenue $ 354,868 $ 320,414 A summary of unallocated corporate expense consists of the following : Three Months Ended March 26, 2016 March 28, 2015 (in thousands) Stock-based compensation $ 6,108 $ 6,280 Compensation, benefits, and other employee-related expenses 12,541 10,696 External consulting and other service expenses 5,176 3,641 Information Technology 3,132 1,864 Depreciation 1,472 1,898 Acquisition and integration 3,763 (362 ) Other general unallocated corporate 3,167 2,137 Total unallocated corporate expense $ 35,359 $ 26,154 Other general unallocated corporate expense consist of various departmental costs including those associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury and investor relations.

Basis of Presentation - Signifi

Basis of Presentation - Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 26, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fiscal Period	The Company’s fiscal year is typically based on a 52 -week year, with each quarter composed of 13 weeks. A 53-week year will occur during the fiscal year 2016, with an additional week included in the fourth quarter.
Use of Estimates	The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, redeemable noncontrolling interest, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Consolidation	The Company’s condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation.
Newly Issued Accounting Pronouncements	In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-09, “Improvements to Employee Share-Based Payment Accounting.” The standard reduces complexity in several aspects of the accounting for employee share-based compensation, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases.” The standard established the principles that lessees and lessors will apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. The ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the full impact this standard will have on its consolidated financial statements and related disclosures but expects to recognize substantially all of its leases on the balance sheet, by recording a right-to-use asset and a corresponding lease liability. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory,” that simplifies the subsequent measurement of inventories by replacing the current lower of cost or market test with a lower of cost or net realizable value test. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers.” The standard, including subsequently issued amendments, will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. The standard will require an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will be effective for annual and interim periods beginning after December 15, 2017. The Company has not yet selected a transition method and is evaluating the impact the adoption will have on its consolidated financial statements and related disclosures.

Business Acquisitions (Tables)

Business Acquisitions (Tables)	3 Months Ended
	Mar. 26, 2016
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	The purchase price allocation of $212.2 million , net of $2.3 million of cash acquired, was as follows: July 24, 2015 (in thousands) Trade receivables (contractual amount of $5,410) $ 5,288 Inventories 10,103 Other current assets (excluding cash) 13,269 Property, plant and equipment 4,639 Definite-lived intangible assets 118,140 Goodwill 105,262 Other long-term assets 537 Short-term debt (9,766 ) Other current liabilities (7,136 ) Long-term liabilities (28,100 ) Total purchase price allocation $ 212,236 The purchase price allocation of $ 35.4 million , net of $ 0.6 million of cash acquired, was as follows: November 18, 2015 (in thousands) Trade receivables (contractual amount of $3,546) $ 3,520 Inventories 129 Other current assets (excluding cash) 706 Property, plant and equipment 2,528 Definite-lived intangible assets 13,330 Goodwill 22,894 Other long-term assets 250 Current liabilities (3,456 ) Long-term liabilities (4,470 ) Total purchase price allocation $ 35,431 The purchase price allocation of $9.6 million , net of less than $0.1 million of cash acquired, was as follows: May 5, 2015 (in thousands) Trade receivables (contractual amount of $995) $ 965 Inventories 1,518 Other current assets (excluding cash) 973 Property, plant and equipment 13,698 Definite-lived intangible assets 3,400 Current liabilities (925 ) Long-term liabilities (250 ) Fair value of net assets acquired 19,379 Bargain purchase gain (9,821 ) Total purchase price allocation $ 9,558
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination	The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 71,000 16 Developed technology 39,140 14 Trademark and trade names 5,200 14 Non-compete 2,800 5 Total definite-lived intangible assets $ 118,140 The breakout of definite-lived intangible assets acquired was as follows: Definite-Lived Intangible Assets Weighted Average Amortization Life (in thousands) (in years) Client relationships $ 7,146 19 Developed technology 5,960 19 Other intangible assets 224 3 Total definite-lived intangible assets $ 13,330

Supplemental Balance Sheet In23

Supplemental Balance Sheet Information (Tables)	3 Months Ended
	Mar. 26, 2016
Supplemental Balance Sheet Information [Abstract]
Composition of Net Trade Receivables	The composition of trade receivables, net is as follows: March 26, 2016 December 26, 2015 (in thousands) Client receivables $ 237,430 $ 230,010 Unbilled revenue 52,134 45,996 Total 289,564 276,006 Less: Allowance for doubtful accounts (2,386 ) (5,938 ) Trade receivables, net $ 287,178 $ 270,068
Composition of Inventories	The composition of inventories is as follows: March 26, 2016 December 26, 2015 (in thousands) Raw materials and supplies $ 17,197 $ 15,998 Work in process 14,295 12,101 Finished products 65,609 65,636 Inventories $ 97,101 $ 93,735
Composition of Other Current Assets	The composition of other current assets is as follows: March 26, 2016 December 26, 2015 (in thousands) Investments $ 18,846 $ 20,516 Prepaid income tax 43,011 26,350 Restricted cash 159 271 Other 148 149 Other current assets $ 62,164 $ 47,286
Composition of Other Assets	The composition of other assets is as follows: March 26, 2016 December 26, 2015 (in thousands) Life insurance policies $ 27,130 $ 27,554 Venture capital investments 37,935 32,730 Restricted cash 1,787 1,745 Other 9,243 9,614 Other assets $ 76,095 $ 71,643
Composition of Other Current Liabilities	The composition of other current liabilities is as follows: March 26, 2016 December 26, 2015 (in thousands) Accrued income taxes $ 15,674 $ 12,168 Accrued interest and other 382 376 Other current liabilities $ 16,056 $ 12,544
Composition of Other Long-Term Liabilities	The composition of other long-term liabilities is as follows: March 26, 2016 December 26, 2015 (in thousands) Long-term pension liability $ 32,494 $ 34,604 Accrued executive supplemental life insurance retirement plan and deferred compensation plan 30,587 30,188 Other 24,283 24,270 Other long-term liabilities $ 87,364 $ 89,062

Venture Capital Investments a24

Venture Capital Investments and Marketable Securities (Tables)	3 Months Ended
	Mar. 26, 2016
Marketable Securities and Equity-Method Affiliates [Abstract]
Schedule of Available-for-sale Securities Reconciliation	The following is a summary of the Company's marketable securities, all of which are classified as available-for-sale: March 26, 2016 Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Mutual fund $ 4,650 $ — $ (98 ) $ 4,552 Total $ 4,650 $ — $ (98 ) $ 4,552 December 26, 2015 Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (in thousands) Mutual fund $ 4,650 $ — $ (141 ) $ 4,509 Total $ 4,650 $ — $ (141 ) $ 4,509

Fair Value (Tables)

Fair Value (Tables)	3 Months Ended
	Mar. 26, 2016
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets, liabilities and redeemable noncontrolling interest measured at fair value on a recurring basis are summarized below: March 26, 2016 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents $ — $ 221 $ — $ 221 Other current assets: Mutual funds 4,552 — — 4,552 Other assets: Life insurance policies — 19,889 — 19,889 Total assets measured at fair value $ 4,552 $ 20,110 $ — $ 24,662 Other current liabilities: Contingent consideration $ — $ — $ 1,114 $ 1,114 Foreign currency forward contracts — 25 — 25 Other long-term liabilities: Contingent consideration — — 200 200 Redeemable noncontrolling interest — — 28,744 28,744 Total liabilities and redeemable noncontrolling interest measured at fair value $ — $ 25 $ 30,058 $ 30,083 December 26, 2015 Level 1 Level 2 Level 3 Total (in thousands) Cash equivalents $ — $ 190 $ — $ 190 Other current assets: Mutual funds 4,509 — — 4,509 Foreign currency forward contracts — 15 — 15 Other assets: Life insurance policies — 20,364 — 20,364 Total assets measured at fair value $ 4,509 $ 20,569 $ — $ 25,078 Other current liabilities: Contingent consideration $ — $ — $ 1,172 $ 1,172 Other long-term liabilities: Contingent consideration — — 198 198 Redeemable noncontrolling interest — — 28,008 28,008 Total liabilities and redeemable noncontrolling interest measured at fair value $ — $ — $ 29,378 $ 29,378
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table provides a rollforward of the fair value of the Company’s redeemable noncontrolling interest related to the acquisition of Vital River. Three Months Ended March 26, 2016 March 28, 2015 (in thousands) Beginning balance $ 28,008 $ 28,419 Additions — — Total gains or losses (realized/unrealized): Net income attributable to noncontrolling interest 198 (130 ) Foreign currency translation (186 ) 78 Change in fair value, included in additional paid-in capital 724 1,086 Ending balance $ 28,744 $ 29,453
Fair Value, Contingent Consideration	The following table provides a rollforward of the contingent consideration related to the business acquisitions. Three Months Ended March 26, 2016 March 28, 2015 (in thousands) Beginning balance $ 1,370 $ 2,828 Additions 600 675 Payments (674 ) — Total gains or losses (realized/unrealized): Reversal of previously recorded contingent liability and change in fair value 18 (717 ) Ending balance $ 1,314 $ 2,786

Goodwill and Other Intangible26

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Mar. 26, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in the Gross Carrying Amount and Accumulated Amortization of Goodwill	The following table provides a rollforward of the Company’s goodwill: Adjustments to Goodwill December 26, 2015 Acquisitions Foreign Exchange March 26, 2016 (in thousands) RMS $ 58,167 $ — $ (14 ) $ 58,153 DSA 247,050 — (1,816 ) 245,234 Manufacturing 133,612 (118 ) (2,825 ) 130,669 Total $ 438,829 $ (118 ) $ (4,655 ) $ 434,056
Schedule of Finite-Lived Intangible Assets	The following table displays intangible assets, net by major class: March 26, 2016 December 26, 2015 Gross Accumulated Amortization Net Gross Accumulated Amortization Net (in thousands) Backlog $ 51,537 $ (51,526 ) $ 11 $ 50,568 $ (50,554 ) $ 14 Technology 56,725 (6,462 ) 50,263 60,350 (5,911 ) 54,439 Trademarks and trade names 11,187 (6,076 ) 5,111 11,495 (5,944 ) 5,551 Other 14,722 (7,611 ) 7,111 14,711 (7,285 ) 7,426 Other intangible assets 134,171 (71,675 ) 62,496 137,124 (69,694 ) 67,430 Client relationships 391,729 (188,841 ) 202,888 396,537 (183,163 ) 213,374 Intangible assets $ 525,900 $ (260,516 ) $ 265,384 $ 533,661 $ (252,857 ) $ 280,804

Long-Term Debt and Capital Le27

Long-Term Debt and Capital Lease Obligations (Tables)	3 Months Ended
	Mar. 26, 2016
Debt Disclosure [Abstract]
Schedule of Debt	Long-term debt, net consists of the following: March 26, 2016 December 26, 2015 (in thousands) Term loans $ 385,000 $ 390,000 Revolving credit facility 452,735 446,041 Other long-term debt 196 193 Total debt 837,931 836,234 Less: current portion of long-term debt (20,196 ) (15,193 ) Long-term debt 817,735 821,041 Debt discount and debt issuance costs (7,091 ) (6,805 ) Long-term debt, net $ 810,644 $ 814,236

Equity (Tables)

Equity (Tables)	3 Months Ended
	Mar. 26, 2016
Equity [Abstract]
Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings Per Share	The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Three Months Ended March 26, 2016 March 28, 2015 (in thousands) Numerator: Income from continuing operations, net of income taxes $ 37,575 $ 31,621 Loss from discontinued operations, net of income taxes (26 ) (7 ) Less: Net income attributable to noncontrolling interests (406 ) (73 ) Net income attributable to common shareholders $ 37,143 $ 31,541 Denominator: Weighted-average shares outstanding - Basic 46,642 46,772 Effect of dilutive securities: Stock options, restricted stock units, performance share units and restricted stock 975 1,096 Weighted-average shares outstanding - Diluted 47,617 47,868
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows: Foreign Currency Translation Adjustment and Other Pension and Other Post-Retirement Benefit Plans Total (in thousands) December 26, 2015 $ (82,977 ) $ (52,571 ) $ (135,548 ) Other comprehensive loss before reclassifications (7,517 ) — (7,517 ) Amounts reclassified from accumulated other comprehensive income (loss) — 390 390 Net current period other comprehensive income (loss) (7,517 ) 390 (7,127 ) Income tax expense — 142 142 March 26, 2016 $ (90,494 ) $ (52,323 ) $ (142,817 )

Pension and Other Post-Retire29

Pension and Other Post-Retirement Benefit Plans Employee Benefits (Tables)	3 Months Ended
	Mar. 26, 2016
Compensation and Retirement Disclosure [Abstract]
Schedule of Net Benefit Costs	The following table provides the components of net periodic cost (benefit) for the Company’s pension plans for the three months ended March 26, 2016 and March 28, 2015 : Pension Plans March 26, 2016 March 28, 2015 (in thousands) Service cost $ 554 $ 1,149 Interest cost 3,364 3,335 Expected return on plan assets (3,992 ) (4,382 ) Amortization of prior service credit (144 ) (151 ) Amortization of net loss 546 880 Net periodic cost $ 328 $ 831

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 26, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation Expense	The following table provides stock-based compensation by the financial statement line item in which it is reflected: Three Months Ended March 26, 2016 March 28, 2015 (in thousands) Cost of revenue $ 1,682 $ 1,501 Selling, general and administrative 8,259 8,173 Stock-based compensation, before income taxes 9,941 9,674 Provision for income taxes (3,514 ) (3,385 ) Stock-based compensation, net of income taxes $ 6,427 $ 6,289

Foreign Currency Contracts (Tab

Foreign Currency Contracts (Tables)	3 Months Ended
	Mar. 26, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Foreign Currency Contracts	The notional amount and fair value of the Company’s foreign currency forward contracts is summarized as follows: Notional Amount Fair Value Balance Sheet Location (in thousands) March 26, 2016 $ 90,412 $ (25 ) Other Current Liabilities December 26, 2015 $ 88,483 $ 15 Other Current Assets
Derivative Instruments, Gain (Loss)	The following table summarizes the effect of foreign exchange forward contracts related to intercompany loans denominated in Euros on the Company’s consolidated statement of income: Three Months Ended March 26, 2016 Location of Gain (Loss) Gain (Loss) Recognized (in thousands) Other income (expense), net $ 2,243

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 26, 2016
Segment Reporting [Abstract]
Schedule of Sales and Other Financial Information by Business Segment	The following table presents revenue and other financial information by reportable segment: Three Months Ended March 26, 2016 March 28, 2015 (in thousands) RMS Revenue $ 124,010 $ 120,011 Operating income 36,533 28,845 Depreciation and amortization 5,281 6,045 Capital expenditures 1,053 2,733 DSA Revenue $ 157,983 $ 140,012 Operating income 30,830 23,516 Depreciation and amortization 11,957 11,139 Capital expenditures 4,707 5,378 Manufacturing Revenue $ 72,875 $ 60,391 Operating income 19,468 16,798 Depreciation and amortization 5,945 3,286 Capital expenditures 2,129 1,566
Reconciliation of Segment Operating Income to Consolidated Operating Income	For the three months ended March 26, 2016 and March 28, 2015 , reconciliations of segment operating income, depreciation and amortization and capital expenditures to the respective consolidated amounts are as follows: Operating Income Depreciation and Amortization Capital Expenditures March 26, 2016 March 28, 2015 March 26, 2016 March 28, 2015 March 26, 2016 March 28, 2015 (in thousands) Total reportable segments $ 86,831 $ 69,159 $ 23,183 $ 20,470 $ 7,889 $ 9,677 Unallocated corporate (35,359 ) (26,154 ) 1,472 1,898 361 971 Total consolidated $ 51,472 $ 43,005 $ 24,655 $ 22,368 $ 8,250 $ 10,648
Schedule of Net Sales for Each Significant Service Area	Revenue for each significant product or service offering is as follows: Three Months Ended March 26, 2016 March 28, 2015 (in thousands) RMS $ 124,010 $ 120,011 DSA 157,983 140,012 Manufacturing 72,875 60,391 Total revenue $ 354,868 $ 320,414
Summary of Unallocated Corporate Overhead	A summary of unallocated corporate expense consists of the following : Three Months Ended March 26, 2016 March 28, 2015 (in thousands) Stock-based compensation $ 6,108 $ 6,280 Compensation, benefits, and other employee-related expenses 12,541 10,696 External consulting and other service expenses 5,176 3,641 Information Technology 3,132 1,864 Depreciation 1,472 1,898 Acquisition and integration 3,763 (362 ) Other general unallocated corporate 3,167 2,137 Total unallocated corporate expense $ 35,359 $ 26,154

Basis of Presentation Basis of

Basis of Presentation Basis of Presentation (Details)	3 Months Ended
	Mar. 26, 2016segments
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments	3

Business Acquisitions- WIL Rese

Business Acquisitions- WIL Research Additional Information (Details) - WIL Research - USD ($) $ in Millions	Apr. 04, 2016	Mar. 26, 2016
Business Acquisition [Line Items]
Integration related costs and transaction costs		$ 4
Subsequent Event
Business Acquisition [Line Items]
Preliminary purchase price	$ 585

Business Acquisitions- Oncotest

Business Acquisitions- Oncotest Additional Information (Details) - Oncotest $ in Thousands, € in Millions	Nov. 18, 2015USD ($)	Mar. 26, 2016EUR (€)	Mar. 26, 2016USD ($)
Business Acquisition [Line Items]
Preliminary purchase price	$ 36,000
Contingent consideration, liability	300
Maximum contingent consideration		€ 2	$ 2,200
Total purchase price allocation	35,431
Cash acquired	$ 600

Business Acquisitions- Oncote36

Business Acquisitions- Oncotest Purchase Price Allocation (Details) - USD ($) $ in Thousands	Mar. 26, 2016	Dec. 26, 2015	Nov. 18, 2015
Business Acquisition [Line Items]
Goodwill	$ 434,056	$ 438,829
Oncotest
Business Acquisition [Line Items]
Acquired receivables, contractual amount			$ 3,546
Trade receivables			3,520
Inventories			129
Other current assets (excluding cash)			706
Property, plant and equipment			2,528
Definite-lived intangible assets			13,330
Goodwill			22,894
Other long-term assets			250
Current liabilities			(3,456)
Long-term liabilities			(4,470)
Fair value of net assets acquired			$ 35,431

Business Acquisitions- Oncote37

Business Acquisitions- Oncotest Definite Lived Intangible Assets (Details) - Oncotest $ in Thousands	Nov. 18, 2015USD ($)
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 13,330
Client relationships
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 7,146
Weighted Average Amortization Life	19 years
Developed technology
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 5,960
Weighted Average Amortization Life	19 years
Other intangible assets
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 224
Weighted Average Amortization Life	3 years

Business Acquisitions - Celsis,

Business Acquisitions - Celsis, Additional Information (Details) - Celsis $ in Thousands	Jul. 24, 2015USD ($)
Business Acquisition [Line Items]
Preliminary purchase price	$ 214,500
Assumed liabilities	10,300
Total purchase price allocation	212,236
Cash acquired	$ 2,300

Business Acquisitions - Celsis

Business Acquisitions - Celsis Purchase Price Allocation (Details) - USD ($) $ in Thousands	Mar. 26, 2016	Dec. 26, 2015	Jul. 24, 2015
Business Acquisition [Line Items]
Goodwill	$ 434,056	$ 438,829
Celsis
Business Acquisition [Line Items]
Acquired receivables, contractual amount			$ 5,410
Trade receivables			5,288
Inventories			10,103
Other current assets (excluding cash)			13,269
Property, plant and equipment			4,639
Definite-lived intangible assets			118,140
Goodwill			105,262
Other long-term assets			537
Short-term debt			(9,766)
Other current liabilities			(7,136)
Long term liabilities			(28,100)
Fair value of net assets acquired			$ 212,236

Business Acquisitions - Celsi40

Business Acquisitions - Celsis Definite-Lived Intangible Assets (Details) - Celsis $ in Thousands	Jul. 24, 2015USD ($)
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 118,140
Client relationships
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 71,000
Weighted Average Amortization Life	16 years
Developed technology
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 39,140
Weighted Average Amortization Life	14 years
Trademark and trade names
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 5,200
Weighted Average Amortization Life	14 years
Non-compete
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 2,800
Weighted Average Amortization Life	5 years

Business Acquisitions - Sunrise

Business Acquisitions - Sunrise, Additional Information (Details) - USD ($) $ in Thousands	May. 05, 2015	Mar. 26, 2016	Mar. 28, 2015
Business Acquisition [Line Items]
Gain on bargain purchase		$ (16)	$ 0
Sunrise
Business Acquisition [Line Items]
Preliminary purchase price	$ 9,558
Gain on bargain purchase	9,821
Cash acquired	$ 100
Sunrise | Client relationships
Business Acquisition [Line Items]
Useful life of intangible assets acquired		15 years

Business Acquisitions - Sunri42

Business Acquisitions - Sunrise Purchase Price Allocation (Details) - USD ($) $ in Thousands	May. 05, 2015	Mar. 26, 2016	Mar. 28, 2015
Business Acquisition [Line Items]
Bargain purchase gain		$ 16	$ 0
Sunrise
Business Acquisition [Line Items]
Acquired receivables, contractual amount	$ 995
Trade receivables	965
Inventories	1,518
Other current assets (excluding cash)	973
Property, plant and equipment	13,698
Definite-lived intangible assets	3,400
Current liabilities	(925)
Long-term liabilities	(250)
Fair value of net assets acquired	19,379
Bargain purchase gain	(9,821)
Total purchase price allocation	$ 9,558

Supplemental Balance Sheet In43

Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Mar. 26, 2016	Dec. 26, 2015
Composition of trade receivables
Client receivables	$ 237,430	$ 230,010
Unbilled revenue	52,134	45,996
Total	289,564	276,006
Less: Allowance for doubtful accounts	(2,386)	(5,938)
Trade receivables, net	287,178	270,068
Composition of inventories
Raw materials and supplies	17,197	15,998
Work in process	14,295	12,101
Finished products	65,609	65,636
Inventories	97,101	93,735
Composition of other current assets
Investments	18,846	20,516
Prepaid income tax	43,011	26,350
Restricted cash	159	271
Other	148	149
Other current assets	62,164	47,286
Composition of other assets
Life insurance policies	27,130	27,554
Venture capital investments	37,935	32,730
Restricted cash	1,787	1,745
Other	9,243	9,614
Other assets	76,095	71,643
Composition of other current liabilities
Accrued income taxes	15,674	12,168
Accrued interest and other	382	376
Other current liabilities	16,056	12,544
Composition of other long-term liabilities
Long-term pension liability	32,494	34,604
Accrued executive supplemental life insurance retirement plan and deferred compensation plan	30,587	30,188
Other	24,283	24,270
Other long-term liabilities	$ 87,364	$ 89,062

Venture Capital Investments a44

Venture Capital Investments and Marketable Securities - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	May. 04, 2016	Mar. 26, 2016	Mar. 28, 2015
Schedule of Equity Method Investments [Line Items]
Committed contribution		$ 65,000,000
Committed contributions funded		31,000,000
Dividends in cash and securities received		$ 0	$ 0
Minimum
Schedule of Equity Method Investments [Line Items]
Ownership percentage		3.60%
Maximum
Schedule of Equity Method Investments [Line Items]
Ownership percentage		12.00%
Subsequent Event
Schedule of Equity Method Investments [Line Items]
Additional committed contributions	$ 10,600,000

Venture Capital Investments a45

Venture Capital Investments and Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 26, 2016	Dec. 26, 2015
Schedule of Available-for-sale Securities [Line Items]
Cost	$ 4,650	$ 4,650
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(98)	(141)
Fair Value	4,552	4,509
Mutual fund
Schedule of Available-for-sale Securities [Line Items]
Cost	4,650	4,650
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(98)	(141)
Fair Value	$ 4,552	$ 4,509

Fair Value - Fair Value of Asse

Fair Value - Fair Value of Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 26, 2016	Dec. 26, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 221	$ 190
Other current assets:
Mutual funds	4,552	4,509
Foreign currency forward contracts		15
Other assets:
Life insurance policies	19,889	20,364
Total assets measured at fair value	24,662	25,078
Other current liabilities:
Contingent consideration	1,114	1,172
Foreign currency forward contracts	25
Other long-term liabilities:
Contingent consideration	200	198
Redeemable noncontrolling interest	28,744	28,008
Total liabilities and redeemable noncontrolling interest measured at fair value	30,083	29,378
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Other current assets:
Mutual funds	4,552	4,509
Foreign currency forward contracts		0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	4,552	4,509
Other current liabilities:
Contingent consideration	0	0
Foreign currency forward contracts	0
Other long-term liabilities:
Contingent consideration	0	0
Redeemable noncontrolling interest	0	0
Total liabilities and redeemable noncontrolling interest measured at fair value	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	221	190
Other current assets:
Mutual funds	0	0
Foreign currency forward contracts		15
Other assets:
Life insurance policies	19,889	20,364
Total assets measured at fair value	20,110	20,569
Other current liabilities:
Contingent consideration	0	0
Foreign currency forward contracts	25
Other long-term liabilities:
Contingent consideration	0	0
Redeemable noncontrolling interest	0	0
Total liabilities and redeemable noncontrolling interest measured at fair value	25	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Other current assets:
Mutual funds	0	0
Foreign currency forward contracts		0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Other current liabilities:
Contingent consideration	1,114	1,172
Foreign currency forward contracts	0
Other long-term liabilities:
Contingent consideration	200	198
Redeemable noncontrolling interest	28,744	28,008
Total liabilities and redeemable noncontrolling interest measured at fair value	$ 30,058	$ 29,378

Fair Value - Redeemable Noncont

Fair Value - Redeemable Noncontrolling Interest (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Total gains or losses (realized/unrealized):
Percentage of voting interests acquired	75.00%
Remaining ownership percentage available	25.00%
Discount rate	18.00%
Percentage change in discount rate	1.00%
Impact on fair value of a 1% increase in discount rate	$ 1,700
Level 3 | Redeemable Noncontrolling Interest
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	28,008	$ 28,419
Additions	0	0
Total gains or losses (realized/unrealized):
Net income attributable to noncontrolling interest	198	(130)
Foreign currency translation	(186)	78
Change in fair value, included in additional paid-in capital	724	1,086
Ending balance	$ 28,744	$ 29,453

Fair Value - Contingent Conside

Fair Value - Contingent Consideration (Details) - Contingent Consideration - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 1,370	$ 2,828
Additions	600	675
Payments	(674)	0
Total gains or losses (realized/unrealized):
Reversal of previously recorded contingent liability and change in fair value	18	(717)
Ending balance	$ 1,314	$ 2,786

Goodwill and Other Intangible49

Goodwill and Other Intangible Assets - Gross Carrying Amount and Accumulated Amortization of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 26, 2016USD ($)
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	$ 438,829
Adjustments to Goodwill, Acquisitions	(118)
Adjustments to Goodwill, Foreign Exchange	(4,655)
Gross carrying amount, balance at the end of the period	434,056
RMS
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	58,167
Adjustments to Goodwill, Acquisitions	0
Adjustments to Goodwill, Foreign Exchange	(14)
Gross carrying amount, balance at the end of the period	58,153
DSA
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	247,050
Adjustments to Goodwill, Acquisitions	0
Adjustments to Goodwill, Foreign Exchange	(1,816)
Gross carrying amount, balance at the end of the period	245,234
Manufacturing
Changes in gross carrying amount and accumulated amortization of goodwill
Gross carrying amount, balance at the beginning of the period	133,612
Adjustments to Goodwill, Acquisitions	(118)
Adjustments to Goodwill, Foreign Exchange	(2,825)
Gross carrying amount, balance at the end of the period	$ 130,669

Goodwill and Other Intangible50

Goodwill and Other Intangible Assets - Schedule of Other Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Dec. 26, 2015	Dec. 27, 2014
Other intangible assets
Gross	$ 525,900		$ 533,661
Accumulated Amortization	(260,516)		(252,857)
Net	265,384		$ 280,804
Impairment charge	1,900
Backlog
Other intangible assets
Gross	51,537	$ 50,568
Accumulated Amortization	(51,526)	(50,554)
Net	11	14
Technology
Other intangible assets
Gross	56,725	60,350
Accumulated Amortization	(6,462)	(5,911)
Net	50,263	54,439
Trademarks and trade names
Other intangible assets
Gross	11,187	11,495
Accumulated Amortization	(6,076)	(5,944)
Net	5,111	5,551
Other
Other intangible assets
Gross	14,722	14,711
Accumulated Amortization	(7,611)	(7,285)
Net	7,111	7,426
Other intangible assets
Other intangible assets
Gross	134,171	137,124
Accumulated Amortization	(71,675)	(69,694)
Net	62,496	67,430
Client relationships
Other intangible assets
Gross	391,729	396,537
Accumulated Amortization	(188,841)	(183,163)
Net	$ 202,888	$ 213,374

Long-Term Debt and Capital Le51

Long-Term Debt and Capital Lease Obligations - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 26, 2016	Dec. 26, 2015
Debt Instrument [Line Items]
Total debt	$ 837,931	$ 836,234
Less: current portion of long-term debt	(20,196)	(15,193)
Long-term debt	817,735	821,041
Debt discount and debt issuance costs	(7,091)	(6,805)
Long-term debt, net	810,644	814,236
Term loans
Debt Instrument [Line Items]
Total debt	385,000	390,000
Revolving credit facility
Debt Instrument [Line Items]
Total debt	452,735	446,041
Other long-term debt
Debt Instrument [Line Items]
Total debt	$ 196	$ 193

Long-Term Debt and Capital Le52

Long-Term Debt and Capital Lease Obligations - Additional Information (Details)	Mar. 30, 2016USD ($)payment	Mar. 26, 2016USD ($)	Mar. 29, 2016USD ($)	Dec. 26, 2015USD ($)	Apr. 30, 2015USD ($)	Mar. 31, 2015USD ($)
Debt Instrument [Line Items]
Credit facility					$ 1,300,000,000	$ 970,000,000
Weighted average interest rate		1.49%		1.33%
Other Capital Lease Obligations
Debt Instrument [Line Items]
Other capital lease obligations		$ 31,100,000		$ 33,600,000
Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding		$ 5,100,000		$ 4,900,000
Federal Funds Rate
Debt Instrument [Line Items]
Interest rate		0.50%
LIBOR
Debt Instrument [Line Items]
Interest rate		1.00%
Subsequent Event
Debt Instrument [Line Items]
Credit facility	$ 1,650,000,000		$ 1,300,000,000
Maximum borrowing capacity, term loan and line of credit facility, potential increase available	$ 500,000,000
Subsequent Event | Federal Funds Rate
Debt Instrument [Line Items]
Interest rate	0.50%
Subsequent Event | LIBOR
Debt Instrument [Line Items]
Interest rate	1.00%
Term Loan Facility
Debt Instrument [Line Items]
Credit facility					400,000,000
Term Loan Facility | Subsequent Event
Debt Instrument [Line Items]
Credit facility	$ 650,000,000
Multi-currency Revolving Facility
Debt Instrument [Line Items]
Credit facility					$ 900,000,000
Multi-currency Revolving Facility | Subsequent Event
Debt Instrument [Line Items]
Credit facility	$ 1,000,000,000
Number of quarterly installment payments | payment	19

Equity - Earnings Per Share (De

Equity - Earnings Per Share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Numerator:
Income from continuing operations, net of income taxes	$ 37,575	$ 31,621
Loss from discontinued operations, net of income taxes	(26)	(7)
Less: Net income attributable to noncontrolling interests	406	73
Net income attributable to common shareholders	$ 37,143	$ 31,541
Denominator:
Weighted-average shares outstanding—Basic (in shares)	46,642	46,772
Effect of dilutive securities: Stock options, restricted stock units, performance share units and restricted stock (in shares)	975	1,096
Weighted-average shares outstanding—Diluted (in shares)	47,617	47,868

Equity - Earnings Per Share, Ad

Equity - Earnings Per Share, Additional Information (Details) - shares shares in Millions	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	1	0.6
Restricted Stock, Restricted Stock Units, and Performance Share Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	1.1	1.2

Equity - Treasury Shares (Detai

Equity - Treasury Shares (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Treasury Shares
Purchase of treasury stock	$ 12,147	$ 58,632
Authorized Share Repurchase Program
Treasury Shares
Stock repurchased during period (in shares)	0	700,000
Purchase of treasury stock		$ 50,000
Remaining authorized repurchase amount	$ 69,700
2007 Incentive Plan
Treasury Shares
Number of shares of common stock repurchased (in shares)	200,000	100,000
Open market repurchases
Treasury Shares
Purchase of treasury stock	$ 12,100	$ 8,600

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Income tax expense	$ 142	$ 217
Foreign Currency Translation Adjustment and Other
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
December 26, 2015	(82,977)
Other comprehensive loss before reclassifications	(7,517)
Amounts reclassified from accumulated other comprehensive income (loss)	0
Net current period other comprehensive income (loss)	(7,517)
Income tax expense	0
March 26, 2016	(90,494)
Pension and Other Post-Retirement Benefit Plans
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
December 26, 2015	(52,571)
Other comprehensive loss before reclassifications	0
Amounts reclassified from accumulated other comprehensive income (loss)	390
Net current period other comprehensive income (loss)	390
Income tax expense	142	$ 217
March 26, 2016	(52,323)
Total
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
December 26, 2015	(135,548)
Other comprehensive loss before reclassifications	(7,517)
Amounts reclassified from accumulated other comprehensive income (loss)	390
Net current period other comprehensive income (loss)	(7,127)
Income tax expense	142
March 26, 2016	$ (142,817)

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Income Tax Disclosure [Abstract]
Effective tax rate (as a percentage)	27.10%	1.00%
Decrease in unrecognized tax benefits	$ (100)	$ (10,400)
Unrecognized tax benefits	23,400
Unrecognized tax benefits that would impact effective tax rate favorably, if recognized	20,100
Accrued interest on unrecognized tax benefits	1,100
Possible decrease of unrecognized tax benefits	3,100
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Income tax expense related to items of other comprehensive income	142	217
Pension and Other Post-Retirement Benefit Plans
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Income tax expense related to items of other comprehensive income	$ 142	$ 217

Pension and Other Post-Retire58

Pension and Other Post-Retirement Benefit Plans (Details) - Pension Plans - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Employee benefits
Service cost	$ 554	$ 1,149
Interest cost	3,364	3,335
Expected return on plan assets	(3,992)	(4,382)
Amortization of prior service credit	(144)	(151)
Amortization of net loss	546	880
Net periodic cost	$ 328	$ 831

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Stock-based compensation expense
Stock-based compensation, before income taxes	$ 9,941	$ 9,674
Provision for income taxes	(3,514)	(3,385)
Stock-based compensation, net of income taxes	6,427	6,289
Cost of revenue
Stock-based compensation expense
Stock-based compensation, before income taxes	1,682	1,501
Selling, general and administrative
Stock-based compensation expense
Stock-based compensation, before income taxes	$ 8,259	$ 8,173

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Grants (Details) shares in Millions	3 Months Ended
	Mar. 26, 2016$ / sharesshares
Stock Options
Stock Issued or Granted During Period, Share-based Compensation [Abstract]
Stock options granted (in shares)	0.6
Stock options weighted average grant date fair value (in dollars per share) | $ / shares	$ 15.04
Restricted Stock Units
Stock Issued or Granted During Period, Share-based Compensation [Abstract]
Shares granted (in shares)	0.2
Weighted-average grant date fair value (in dollars per share) | $ / shares	$ 73.71
Performance Stock Units
Stock Issued or Granted During Period, Share-based Compensation [Abstract]
Shares granted (in shares)	0.2
Weighted-average grant date fair value (in dollars per share) | $ / shares	$ 79.81
Maximum shares to be awarded under plan	0.4

Foreign Currency Contracts - No

Foreign Currency Contracts - Notional Amount and Fair Value (Details) - Foreign Exchange Contract - USD ($) $ in Thousands	Mar. 26, 2016	Dec. 26, 2015
Derivative [Line Items]
Other current liabilities, notional amount	$ 90,412
Other current assets, notional amount		$ 88,483
Other Current Liabilities
Derivative [Line Items]
Other current liabilities, fair value	$ (25)
Other Current Assets
Derivative [Line Items]
Other current assets, fair value		$ 15

Foreign Currency Contracts - Ef

Foreign Currency Contracts - Effect on Statement of Income (Details) $ in Thousands	3 Months Ended
	Mar. 26, 2016USD ($)
Derivatives, Fair Value [Line Items]
Remaining maturity range	1 month
Other income (expense), net | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Gain (Loss) Recognized	$ 2,243

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	3 Months Ended
	Mar. 26, 2016USD ($)patent
Loss Contingencies [Line Items]
Increase in lease obligations	$ 3.3
Government billing
Loss Contingencies [Line Items]
Reserve for estimated possible loss	$ 1.5
Pending Litigation | Idexx
Loss Contingencies [Line Items]
Number of patents infringed upon | patent	3

Segment Information - Revenue a

Segment Information - Revenue and Other Financial Information by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Segment Reporting Information [Line Items]
Revenue	$ 354,868	$ 320,414
Operating income	51,472	43,005
Depreciation and amortization	24,655	22,368
Capital expenditures	8,250	10,648
Operating segments
Segment Reporting Information [Line Items]
Operating income	86,831	69,159
Depreciation and amortization	23,183	20,470
Capital expenditures	7,889	9,677
RMS | Operating segments
Segment Reporting Information [Line Items]
Revenue	124,010	120,011
Operating income	36,533	28,845
Depreciation and amortization	5,281	6,045
Capital expenditures	1,053	2,733
DSA | Operating segments
Segment Reporting Information [Line Items]
Revenue	157,983	140,012
Operating income	30,830	23,516
Depreciation and amortization	11,957	11,139
Capital expenditures	4,707	5,378
Manufacturing | Operating segments
Segment Reporting Information [Line Items]
Revenue	72,875	60,391
Operating income	19,468	16,798
Depreciation and amortization	5,945	3,286
Capital expenditures	$ 2,129	$ 1,566

Segment Information - Reconcili

Segment Information - Reconciliation of Segment Operating Income, Depreciation and Amortization, and Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Segment Reporting Information [Line Items]
Operating income	$ 51,472	$ 43,005
Depreciation and amortization	24,655	22,368
Capital expenditures	8,250	10,648
Operating segments
Segment Reporting Information [Line Items]
Operating income	86,831	69,159
Depreciation and amortization	23,183	20,470
Capital expenditures	7,889	9,677
Unallocated corporate
Segment Reporting Information [Line Items]
Operating income	(35,359)	(26,154)
Depreciation and amortization	1,472	1,898
Capital expenditures	$ 361	$ 971

Segment Information - Revenue P

Segment Information - Revenue Per Significant Product or Service (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Segment Reporting Information [Line Items]
Revenue	$ 354,868	$ 320,414
Operating segments | RMS
Segment Reporting Information [Line Items]
Revenue	124,010	120,011
Operating segments | DSA
Segment Reporting Information [Line Items]
Revenue	157,983	140,012
Operating segments | Manufacturing
Segment Reporting Information [Line Items]
Revenue	$ 72,875	$ 60,391

Segment Information - Summary o

Segment Information - Summary of Unallocated Corporate Overhead (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 26, 2016	Mar. 28, 2015
Segment Reporting Information [Line Items]
Stock-based compensation	$ 9,941	$ 9,674
Unallocated corporate
Segment Reporting Information [Line Items]
Stock-based compensation	6,108	6,280
Compensation, benefits, and other employee-related expenses	12,541	10,696
External consulting and other service expenses	5,176	3,641
Information Technology	3,132	1,864
Depreciation	1,472	1,898
Acquisition and integration	3,763	(362)
Other general unallocated corporate	3,167	2,137
Total unallocated corporate expense	$ 35,359	$ 26,154